Casdin Capital

Casdin Capital
Name	Casdin Capital
Type	Private
Industry	Investment Management
Founded	2015
Headquarters	New York City, New York
Products	Investment funds

Casdin Capital is a New York–based investment firm specializing in healthcare and biotechnology equity investments. The firm focuses on private and public companies involved with drug discovery, biopharmaceutical development, diagnostics, and medical technologies. Casdin targets entrepreneurs, boards, and scientific teams across translational medicine, often engaging with venture capital firms, institutional investors, and academic spinouts.

History

Casdin Capital was founded in 2015 amid a rising interest in biotechnology investing driven by advances at institutions such as Harvard University, Massachusetts Institute of Technology, Stanford University, and biotech clusters like Cambridge, Massachusetts and San Francisco. The firm built relationships with venture firms including Sequoia Capital, Kleiner Perkins, Third Rock Ventures, and Flagship Pioneering while interacting with translational research from organizations such as Broad Institute, Cold Spring Harbor Laboratory, and Genentech. Early fundraising took place alongside limited partners from endowments like Yale University and Harvard Management Company as well as family offices and sovereign wealth entities similar to Qatar Investment Authority and Temasek Holdings. Casdin expanded during biotech IPO waves on exchanges such as the New York Stock Exchange and NASDAQ, participating in private rounds and crossover financings linked to precedent deals from firms like Amgen, Gilead Sciences, Roche, and Novartis.

Investment Strategy and Focus

The firm's strategy emphasizes biopharma discovery, clinical-stage assets, platform technologies, and diagnostics. Casdin sources opportunities from incubators such as IndieBio and Johnson & Johnson Innovation, university tech transfer offices including Columbia Technology Ventures and Oxford University Innovation, and translational funds like Santander InnoVentures and Novo Holdings. Investment activity often engages regulatory and scientific milestones tied to agencies and frameworks like the U.S. Food and Drug Administration, European Medicines Agency, and landmark trials analogous to SOLAR-1 and EMERGE. The firm allocates capital across private equity-style growth rounds, crossover investments similar to SoftBank Vision Fund activity, and public equity positions reminiscent of hedge fund engagements such as those by Billionaire activist investors and Carl Icahn-style campaigns.

Notable Investments and Portfolio Companies

Casdin has invested in companies spanning therapeutic modalities and platform technologies. Portfolio names have included biotech companies and diagnostics ventures comparable to Moderna, CRISPR Therapeutics, Illumina, Regeneron Pharmaceuticals, and smaller clinical-stage firms akin to Alnylam Pharmaceuticals and Bluebird Bio. The firm has been associated with investments in cell therapy and gene-editing startups that resonate with work at CRISPR-Cas9 research centers, collaborations with contract research organizations similar to Charles River Laboratories, and partnerships involving biomanufacturing entities like Catalent. Casdin’s activity often parallels syndicates that include Arch Venture Partners, Atlas Venture, GV (venture capital), and crossover investors active during Biotech IPO cycles.

Leadership and Key Personnel

Leadership draws on professionals experienced in life sciences, capital markets, and institutional investing. The firm interacts with executives and advisors who have backgrounds at major biopharma companies such as Pfizer, Merck & Co., Johnson & Johnson, and Eli Lilly and Company, and with clinicians from academic centers including Johns Hopkins Hospital, Mayo Clinic, and Memorial Sloan Kettering Cancer Center. Senior team members often maintain networks with venture leaders from OrbiMed Advisors, Perceptive Advisors, and New Enterprise Associates, as well as capital markets figures from Goldman Sachs, J.P. Morgan, and Morgan Stanley.

Performance, Funds, and Financials

Casdin raises funds structured for accredited and institutional investors, aligning with limited partners similar to Pension Protection Act-era allocations and endowment strategies used by Princeton University and Stanford Management Company. Fund performance is benchmarked against indices tracking biotechnology and healthcare equities like the NASDAQ Biotechnology Index and broader indices such as the S&P 500. The firm’s vehicles participate in private secondary transactions, crossover financing rounds, and public equity positions that mirror activity by Hedge funds specializing in life sciences. Capital deployment often coincides with market events involving Initial Public Offering windows, merger and acquisition activity similar to Bristol-Myers Squibb acquisitions, and strategic alliances like those between Pfizer and BioNTech.

Controversies and Legal Matters

Casdin has been referenced in reporting and regulatory filings in the context of activist engagement, short- and long-position disclosures, and market-moving statements typical of high-profile healthcare investors. Such matters invoke regulatory frameworks and legal precedents involving entities like the U.S. Securities and Exchange Commission, litigation models seen in cases involving Securities fraud allegations, and disclosure practices parallel to those scrutinized in matters involving firms such as Pershing Square Capital Management and Engine Capital. The firm’s activity has intersected media coverage from outlets like The Wall Street Journal, Bloomberg L.P., and The New York Times when portfolio companies undergo clinical setbacks, FDA decisions, or strategic transactions similar to those affecting Theranos-era scrutiny or high-profile biotech restructurings.

Category:Investment management companies